Advertisement
Australia markets closed
  • ALL ORDS

    8,153.70
    +80.10 (+0.99%)
     
  • ASX 200

    7,896.90
    +77.30 (+0.99%)
     
  • AUD/USD

    0.6512
    -0.0024 (-0.37%)
     
  • OIL

    82.35
    +1.00 (+1.23%)
     
  • GOLD

    2,227.50
    +14.80 (+0.67%)
     
  • Bitcoin AUD

    108,706.28
    +2,418.93 (+2.28%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • AUD/EUR

    0.6026
    -0.0005 (-0.08%)
     
  • AUD/NZD

    1.0895
    +0.0015 (+0.14%)
     
  • NZX 50

    12,105.29
    +94.63 (+0.79%)
     
  • NASDAQ

    18,268.73
    -12.11 (-0.07%)
     
  • FTSE

    7,961.73
    +29.75 (+0.38%)
     
  • Dow Jones

    39,748.29
    -11.79 (-0.03%)
     
  • DAX

    18,498.40
    +21.31 (+0.12%)
     
  • Hang Seng

    16,541.42
    +148.58 (+0.91%)
     
  • NIKKEI 225

    40,168.07
    -594.66 (-1.46%)
     

Genetic Technologies CEO to Participate in Investor Webinar and Q&A Session on June 24, 2020

MELBOURNE, Australia, June 23, 2020 (GLOBE NEWSWIRE) -- Molecular diagnostics company Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE) (the “Company”) is pleased to announce that its interim-CEO Dr. George Muchnicki will share insight into the Company’s recent developments during an investor webinar, hosted by RedChip Companies, on Wednesday, June 24, 2020 at 4:00 p.m. ET. A live Q&A session with Dr. Muchnicki will follow the presentation.

To register for the free webinar, please visit: https://www.redchip.com/corporate/webinar_register/63

About Genetic Technologies Limited

Genetic Technologies Limited (ASX: GTG; Nasdaq: GENE) is a diversified molecular diagnostics company. GTG offers cancer predictive testing and assessment tools to help physicians proactively manage patient health. The Company’s lead products GeneType for Breast Cancer for non-hereditary breast cancer and GeneType for Colorectal Cancer are clinically validated risk assessment tests and are first in class.

ADVERTISEMENT

Genetic Technologies has capacity for COVID-19 testing and is developing a pipeline of risk assessment products.

For more information, please visit www.gtglabs.com.

Contact:
Dave Gentry, CEO
RedChip Companies
Office: 1 800 RED CHIP (733 2447)
Cell: US 407 491 4498
dave@redchip.com